Sep 29, 2026
Novo Nordisk (NVO) Stock: $2.6B Deal Secures Chinese Obesity Pill Rights
Novo Nordisk (NVO) secures global rights to Chinese obesity pill HRS-1596 in $2.6B deal with Hengrui as competition with Eli Lilly intensifies.
The post Novo Nordisk (NVO) Stock: $2.6B Deal Secures Chinese Obesity Pill Rights appeared first on Blockonomi.
Source: Blockonomi →Related News
- 54 minutes ago
Rocket Lab (RKLB) Stock: Surges as Electron Completes 98th Launch for HawkEye 36...
- 3 hours ago
Cosmos (ATOM) Price Prediction: Can ATOM Reach $15?
- 3 hours ago
XRP News: Why Korea’s KYC-Ready Traders Could Fast-Track XRP Tokenization
- 6 hours ago
Robinhood sees surge in bitcoin, gold prediction markets as traders move beyond...
- 6 hours ago
Bitcoin Price Prediction: When Will BTC Hit $100K Again?